In the rapidly evolving landscape of genetic medicine, gene replacement mRNA synthesis service has emerged as a transformative modality for treating inherited and acquired disorders. Unlike traditional gene therapies that rely on viral vectors for DNA integration, messenger RNA (mRNA) offers a transient, non-integrative approach to restoring protein function. At CD BioGlyco, we specialize in the high-fidelity synthesis of mRNA tailored specifically for protein replacement applications. By delivering a functional transcript directly to the cytoplasm, our service enables the cellular machinery to produce therapeutic proteins, bypassing the risks of genomic mutation.
As a leader in the therapeutic nucleic acid development platform, CD BioGlyco leverages years of expertise in RNA biology to provide researchers with optimized mRNA constructs. Our service is designed to address the primary challenges of mRNA therapeutics: stability, translational efficiency, and immunogenicity. Through advanced sequence engineering and chemical modifications, we ensure that every mRNA molecule is a potent tool for genetic restoration.
Within our therapeutic nucleic acid development platform, the therapeutic oligonucleotide synthesis service focuses on providing comprehensive solutions for gene replacement. Our scope includes:
The process begins with the digital design of the DNA template. We utilize AI-driven algorithms to optimize codons and secondary structures. The resulting sequence is cloned into a high-copy plasmid or synthesized as a linear double-stranded DNA (dsDNA) fragment.
For plasmid-based templates, the DNA is linearized using high-fidelity restriction enzymes. This ensures that the IVT process terminates accurately at the end of the poly(A) sequence, preventing untemplated extensions that could interfere with mRNA function.
Using the linearized template, the IVT reaction is performed under optimized conditions. We monitor the concentration of magnesium ions (Mg2+) and NTPs in real-time to maximize yield while maintaining the integrity of the transcript.
If co-transcriptional capping is not selected, we utilize enzymatic capping systems to add the 5' cap structure. Similarly, enzymatic poly(A) tailing is performed to reach specific tail lengths, typically ranging from 120 to 200 nucleotides.
We utilize tangential flow filtration (TFF) and high-performance liquid chromatography (HPLC) to remove residual DNA templates, enzymes, unreacted NTPs, and double-stranded RNA (dsRNA) byproducts. This ensures the removal of impurities that could trigger unwanted immune responses.
Every batch undergoes stringent QC, including fragment analysis for integrity, HPLC for purity, and endotoxin testing. We also verify the sequence and concentration to ensure the final product meets the exact specifications required for gene replacement studies.
DoI: 10.3389/fonc.2019.01208
Journal: Frontiers in Oncology
IF: 3.3
Published: 2019
Results: This review explores the therapeutic potential of mRNA-based gene therapy for glioblastoma (GBM), an aggressive and hard-to-treat brain tumor with high heterogeneity, invasiveness, and resistance to conventional therapies. mRNA therapy offers distinct advantages over DNA-based approaches, including easy manipulation, rapid and transient expression, no insertional mutagenesis risk, and suitability for both dividing and non-dividing cells. The article details in vitro mRNA synthesis using elements like anti-reverse cap analogs (ARCA) caps and poly(A) tails, and various delivery systems such as naked mRNA, lipoplexes, inorganic nanoparticles, polypeptides, viruses, cell-mediated carriers, and exosomes. mRNA-based therapy enables multi-level targeting of GBM and personalized administration routes. Despite challenges like in vivo stability and targeted delivery, ongoing clinical trials in related fields support its promising outlook as a novel treatment for GBM.
Fig.1 mRNA synthesization in vitro. (Tang, et al., 2019)
Rare Genetic Disorders
mRNA synthesis provides a rapid path to developing therapies for monogenic diseases like cystic fibrosis or hemophilia. By replacing the defective protein, our mRNA constructs restore biological function without permanent genomic alteration.
Metabolic Disease Research
We support research into inborn errors of metabolism, such as phenylketonuria (PKU). Our high-purity mRNA enables the transient expression of metabolic enzymes in the liver, offering a potent tool for therapeutic discovery.
Neuromuscular Therapy Development
CD BioGlyco synthesizes specialized mRNA for the treatment of neuromuscular conditions. These constructs are designed for high stability, ensuring sustained protein production in difficult-to-transfect tissues like skeletal muscle and neurons.
Immunological Rejuvenation
Our services extend to the production of mRNA encoding regulatory factors that restore immune function. This is particularly relevant for age-related immune decline or restoring T-cell activity in oncology research.
Exceptional Purity Levels
We utilize dual-stage purification (TFF and HPLC) to eliminate dsRNA and other synthesis byproducts. This results in mRNA with minimal immunogenicity and maximum translational efficiency for sensitive gene replacement applications.
Fully Customizable Sequences
Our platform allows for complete control over UTRs, ORF optimization, and poly(A) tail length. This flexibility ensures that the mRNA is perfectly tuned to the specific biological requirements of your project.
Reduced Immunogenicity
Through the strategic incorporation of modified nucleotides like m1ψ and optimized capping, we produce mRNA that avoids detection by innate immune sensors. This is critical for achieving high protein expression levels.
Scalable Production Capacities
Whether you require microgram quantities for pilot studies or gram-scale production for preclinical trials, CD BioGlyco scales our processes to meet your needs without compromising on quality or turnaround.
"The purity of the mRNA provided by CD BioGlyco for our cystic fibrosis research was outstanding. We saw a significant reduction in the inflammatory response compared to our previous suppliers, allowing us to accurately measure protein restoration levels."
– B.G., Principal Investigator
"We utilized the gene replacement mRNA synthesis service for a metabolic disorder study. The turnaround time was impressive, and the technical support team helped us optimize the 3' UTR for better stability in hepatocyte cultures."
– A.H., Senior Scientist
"Working with CD BioGlyco's therapeutic nucleic acid development platform has been a game-changer for our lab. Their ability to handle large-scale synthesis with consistent QC data has allowed us to move into animal trials much faster than anticipated."
– S.G., Director of Research
CD BioGlyco is dedicated to advancing the field of genetic medicine through our gene replacement mRNA synthesis service. By combining state-of-the-art IVT technology, advanced purification, and deep expertise in RNA modifications, we provide the high-fidelity tools necessary to restore biological function and transform patient lives. Please feel free to contact us for more information about our services or to request a customized quote.
Reference
